



Selected HPR Pain Publications & presentations (out of the overall HPR list on CNS & Pain)

(from 1987 – Q4/2020)


1. Schaffler, K., Reeh, P.W., Zentzis, K., & Hamperl, W. (1987). Analgesic effect of ASA vs a Lithium-ASA combination: An evoked potential study employing radiant heat stimulation with a CO₂ laser. *Pharmacopsychiatry*, 20, 217-221.
2. Klausnitzer, W., & Schaffler, K. (1988). Randomised placebo-controlled double-blind 5-period crossover study on analgesic properties of three acute oral doses of CM 40907 (anti-epileptic) and ASA - employing CO₂-Laser for noci-stimulation. C.I.N.P. Congress, Munich 1988. *Sonderdruck*, (abstract)
3. Schaffler, K., & Klausnitzer, W. (1989). Analgesic effect of two oral doses of Ro 12-9150 (Kappa-Agonist) vs pentazocine: an evoked potential study employing CO₂-laser and electro-dermal stimulation. *Sonderdruck* (abstract)
4. Schaffler, K., & Klausnitzer, W. (1989). Analgesic effects of parenterally administered Ro 12-9150 vs pentazocine: an evoked potential study employing CO₂-laser and electro-dermal stimulation. *Sonderdruck*, (Abstract)
5. Rehn, D., & Schaffler, K. (1990). The Local Anaesthetic Activity of the H₁-Receptor Antagonist Dimethindene Maleate. Satell. Symp. of the XIth Int. Congr. of Pharmacol. of Iuphar/Holl., July 1990. *New Perspectives in Histamine Research*, (abstract)
6. Rehn, D., & Schaffler, K. (1990). Zur lokalanästhetischen Wirkung des H₁-Rezeptor-Antagonisten Dimethindenmaleat (Fenistil). Abstract, Europ. Histaminkongress Marburg, Mai 1991. *Sonderdruck*, (abstract)
7. Schaffler, K., Wauschkuhn, C.H., & Gierend, M. (1991). Analgesic potency of a new anticonvulsant drug versus acetylsalicylic acid via laser somatosensory evoked potentials. Randomised placebo-controlled double-blind (5-way) crossover study. *Arzneim -Forsch /Drug Res*, 41 (I), 4, 427-435.
8. Schaffler, K., Wauschkuhn, C.H., & Rehn, D. (1991). The Local Anaesthetic Activity of Dimethindene. the Dimethindene Maleate's Investigators' Meeting, Zürich, Switzerland, May 25, 1991, organized by Zyma SA. *Sonderdruck*, (abstract)
9. Rehn, D., Brunbauer, H., Wauschkuhn, C.H., & Schaffler, K. (1992). Zur topischen Wirkung des Antihistaminikums Dimethindenmaleate (Fenistil®). *Pharmazeutische Zeitung*, 5,5/137, 215-217.
10. Schaffler, K., Wauschkuhn, C.H., Brunbauer, H., & Rehn, D. (1992). Evaluation of the local anaesthetic activity of dimethindene maleate by means of laser algesimetry in healthy volunteers. *Arzneim-Forsch /Drug Res*, 42 (II), Nr. 11, 1332-1335.
11. Schaffler, K., Wauschkuhn, C.H., & Brunbauer, H. (1992). An explorative evaluation of the local-anaesthetic activity of Dimethindene. *Agents & Actions, Special Conf. Iss. C* 437-C 439.
12. Brunbauer, H., Schaffler, K., Wauschkuhn, C.H., Jarms, G., & Rehn, D. (1993). Dimethindene Maleate in the treatment of cutaneous reactions - caused by experimental exposure to jellyfish (cyanea capillata) using VAS, colorimetry and calorimetry in volunteers. European Histamine Research Society, XXII. Annual Meeting, Cologne, 19-22 May, 1993. *Conference Papers, I*, (abstract)




13. Schaffler, K. (1993). Alternativen zur klinischen Prüfung am Patienten bei nicht-dermalen Topika. Symposium "Topika - vom Antacidum bis zum Lokalcorticoid" der Arbeitsgemeinschaft für pharmazeutische Verfahrenstechnik e.V. (APV), Darmstadt, 21.-22. Oktober 1993. *Sonderdruck*, (abstract)
14. Schaffler, K., Wauschkuhn, C.H., & Jurna, I. (1993). Evaluation of Analgesic Potency of Oral Lysine Clonixinate vs Ibuprofen - Using Objective Laser-SEP-Algesimetry in Healthy Volunteers. 7th World Congress on Pain. August 22-27, 1993, Paris, France. *IASP*, (abstract)
15. Schaffler, K. (1994). Lokalanästhetische Potenz von Fenistil-Gel höher als von Lidocain. Referat 22. Jahrestagung European Histamine Research Society, Köln, 19.-22.5.1993. *Sonderdruck*, 4 (abstract)
16. Schaffler, K. (1994). Evoked potentials, pain and analgesics. 1ra. Conferencia Internacional sobre Dolor. Buenos Aires, 19 y 20 de abril de 1994. *Sonderdruck*, 26-29. (abstract)
17. Schaffler, K., Medert, G. (1998). The analgesic, anti-inflammatory profile of dexketoprofen trometamol (vs tramadol). *Der Schmerz*, Bd.12, S1/98, 69-70 Abstract, Dt. Schmerzkongress 1998 Düsseldorf, October 14-18 (1998)
18. Schaffler, K. (1998). The Contribution of Pharmacodynamic Methodology in Pain Research. OTC Scientific Workshop, Parsippany NJ, USA, October 22 (1998) Abstract
19. Schaffler, K., Beckers, C., Unkauf, M., Kyrein H.-J. (1999). Dimethindene maleate in the treatment of sunburn – a double-blind, placebo-controlled pilot study. *Arzneim-Forsch /Drug Res.* 49 (I), Nr. 4, 374-379 (1999)
20. Schaffler, K., (1999). Erkenntnisse zur Schmerzverarbeitung aus subjektiven und objektiven Messverfahren. Dt. Neurologentag Marburg, 7.-9.5.99, Abstract-Band S.27, Abstract (1999)
21. Schaffler, K., (2000). The analgesic effect of a selective NARI in a Laser-capsaicin model, Dt. Schmerztag 2000, 3/2000 Frankfurt/M., Abstr. In *Pain*, 40
22. Schüler, P., Schaffler K., Seibel, K., Analgetische Wirksamkeit von Reboxetin, DGPPN Kongress 2000, Dt. Ges. für Psychiatrie, Psychotherapie und Nervenheilkunde, Aachen, 20.-23. Sept. 2000, Abstr., *Der Nervenarzt*, 71 (suppl.1), 132 (2000)
23. Thomsen MS, Hansen AJ, Olsen UB, Reeh P, Schaffler K and Seibel K, Effects of ReN1869 on Capsaicin and Histamine Induced Neurogenic Inflammation in Healthy Male Subjects. Poster Edinburgh Inflammation Congress, Sept. 2001
24. Schaffler, K., Seibel, K., Edwards, M., Study to evaluate the effect of ReN 1869 on the development of capsaicin-induced hyperalgesia in human skin -a study using laser-induced somatosensory evoked potentials (LSEPs), Deutscher Schmerzkongress Berlin, Oct. 2001, Poster, Abstract (in "Der Schmerz")
25. Peter Schüler, Klaus Seibel, Vitali Chevts, Klaus Schaffler, (2002) Analgetische Wirkung des selektiven Noradrenalin-Wiederaufnahmehemmers Reboxetin - Objektive und subjektive Messung, *Der Nervenarzt*, 73: 149-154
26. MS Thomsen, AJ Hansen, UB Olsen, P Reeh, S. Ingwersen, K Schaffler and K. Seibel, Effects of ReN1869 on capsaicin and histamine induced neurogenic inflammation in healthy subjects. *Drug Development Research*, 2002, 57 (4):193-197
27. Schaffler K., Advances in Experimental Human Pain Models and Pain Research - Accentuating Inflammatory and Neuropathic Pain, Presentation IIR CNS Drug Development Conference, London, 04/2002



28. Schaffler K., Aktuelle Studienergebnisse: Ibuprofen und Ibuprofen-Lysinat. Gibt es relevante Unterschiede? 1. Petersberger Schmerztage, 11. und 12. November 2003, Petersberg/Bonn
29. Schaffler K., Seibel K., Thomsen M. and Edwards M., Effect of the New H1-Antagonist ReN1869 on the capsaicin-induced hyperalgesia in human skin: Human phase-I trial using somatosensory evoked potentials induced by a CO2 laser, *Drug Res.* 54, No.3, 187-191, 2004
30. Schaffler K., Overcoming the challenges associated with pain measurement and treatment (presentation), (+ breakfast workshop: Reviewing the value of models and biomarkers in early development to assess pain), IIR Conference: Leveraging CNS Product Development, Amsterdam 31.3.-1.4. 2004
31. Schaffler K., Reitmeir P., Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia. A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory evoked potentials (LSEPs) obtained from capsaicin-irritated skin in healthy volunteers, *Drug Res.* 54, No 10, 673-679, 2004
32. Seibel K., Schaffler K., Reeh P., Reitmeir P., Comparison of two different preparations of ibuprofen with regard to the time course of their analgesic effect – using laser somatosensory evoked potentials from UV-irritated skin in healthy volunteers, *Drug Res.* 54, No.8, 444-451, 2004
33. Klaus Schaffler, Peter Reitmeir, Andrea Gschanes, Udo Eggenreich, Comparison of the analgesic effects of NEODOLPASSE® with its compounds diclofenac and orphenadrine, a placebo-controlled study using Laser-induced somatosensory evoked potentials from human skin in the state of capsaicin hyperalgesia, *Drugs R D*, 6 (4): 189-199, 2005
34. K. Schaffler. Drug effects on Laser-evoked nociceptive EEG-responses obtained from UV- and capsaicin-irritated skin of healthy humans, Abstract and Poster, Keystone symposia: “Pain mechanisms and the development of analgesics” 11.-16.06.2006, Keystone Resort Colorado USA
35. P.C.C.M. Passier, B. Schaffler, K. Schaffler, P.W. Reeh, Combination of radiant heat (LASER) and auditory evoked potentials with visual analog scales differentiates between antinociceptive and sedative drug effects, Abstract and Poster Dutch Society of Clinical Pharmacology and Biopharmacy, Utrecht Mar 2007, *Br J Clin Pharmacol*, 65:2, 290, 2008
36. K. Schaffler, Validation study using Laser somatosensory evoked potentials (LSEP) in UV-skin model to investigate the efficacy of prescription and non-prescription analgesics, Abstract and Poster at British Pain Society, Liverpool, Apr. 2008
37. K. Schaffler, Laser Somatosensory Evoked Potentials (LSEP) in UV-Skin model to classify efficacy of some prescription and non-prescription analgesics, Abstract and Poster at IASP World Congress on Pain, Glasgow, Aug. 2008
38. K. Schaffler, Proof of efficacy and dose-dependency of NSAID and opiate analgesics in Laser evoked potential paradigm - using capsaicin and UV skin model, invited speech, Spring Pain Conference, Grand Cayman Island, Apr./May 2008, in *Brain Research Reviews*, Elsevier, Session Predicting Therapeutic Efficacy & Experimental Pain in Human Subjects, *Brain Res Rev.* 2009;60:243-54. available online: 31-DEC-2008, DOI: 10.1016/j.brainresrev.2008.12.016




39. Hoeben, E., Smit, J.W., Upmalis, D., Schaffler, K. and Mangold, B. Dose-response relationship after administration of single oral doses of tapentadol in a human pain model using Laser Somatosensory Evoked Potentials (LSEPs) on UVB-irradiated and capsaicin-irritated skin in healthy male subject, Abstract and Poster Keystone Symposium “The Neurobiology of Pain and Analgesia”, Santa Fé, Febr. 22-26 2009
40. K. Schaffler, Efficacy ranking of some prescription and non-prescription analgesics using Laser-somatosensory evoked potentials in UV-skin, Abstract and Poster at Keystone Symposium “The Neurobiology of Pain and Analgesia”, Santa Fé, Febr. 22-26 2009
41. Master, Peachey, Schaffler, Graham, Routledge. Analgesic effect of the novel, potent and selective prostanoid EP₄ receptor antagonist, BGC20-1531: a placebo-controlled study using Laser-induced somatosensory-evoked potentials obtained from UV_B and capsaicin irritated skin in healthy volunteers, Abstract and Poster at the 18th Int. Headache Research Seminar, March 6-8 2009, Copenhagen, Denmark, European Journal of Pain Supplements 04/2010; 4(1):111-11
42. K. Schaffler, Laser, Auditory Evoked Potentials and Visual Analogue Scales Differentiate Antinociceptive from Sedative Drug Effects, Abstract and Poster at “Pain in Europe VI” 6th Congress of the European Federation of IASP Chapters (EFIC), Lisbon, Portugal, September 9-12, 2009
43. K. Schaffler, Analgesic Effects of the Selective Prostanoid EP₄-Receptor Antagonist, BGC20-1531 Using Laser Somatosensory-Evoked Potentials From UVB- and Capsaicin-Irritated Skin in Volunteers, abstract and poster at 3rd International Congress on Neuropathic Pain (NeuPSIG 2010) Athens, Greece, May 27-30, 2010
44. K. Schaffler, W.R. Duan, A.E. Best, C.R. Faltynek, C. Locke, W. Nothaft, Effects of a novel TRPV-1 antagonist ABT-102 in human experimental pain study using laser somatosensory evoked potentials obtained from UVB-irritated and normal skin in healthy volunteers, Abstract and Poster 13th World Congress on Pain (IASP), Montreal, Canada, August 29th – September 2nd 2010
45. K. Schaffler, W.R. Duan, A.E. Best, C.R. Faltynek, C. Locke, W. Nothaft. Effects of a novel TRPV-1 antagonist ABT-102 in a human experimental pain study using laser somatosensory evoked potentials obtained from UVB-irritated and normal skin in healthy volunteers, Br J Clin. Pharm, 2012, 75:2, 404-414 (DOI: 10.1111/j.1365-2125.2012.04377.x)
46. E. Hoeben, J. W. Smit, D. Upmalis, S. Rush, K. Schaffler, P. Reitmeir and B. Mangold. Analgesic/Anti-hyperalgesic Efficacy and Dose-Response Relationship of Morphine and Oxycodone Immediate Release in a Human Experimental Algesimetric Model, Abstract and Poster at 7th Congress of the European Federation of IASP Chapters (EFIC)-Pain in Europe VII Hamburg, Germany, September 21-24, 2011
47. E. Hoeben, J. W. Smit, D. Upmalis, S. Rush, K. Schaffler, P. Reitmeir and B. Mangold. Dose-response relationship after single oral dose administrations of morphine and oxycodone IR in a human experimental algesimetric model using laser evoked potentials on UVB-irradiated and capsaicin-irritated skin, PAIN 153, 2012, 1648–1656
48. K. D. Schaffler, M. S, Lee, M. Versavel. First clinical translation of the anti-nociceptive/anti-hyperalgesic efficacy of a T-type calcium channel modulator (Z944) – using Laser evoked potentials and VAS in UV_B and capsaicin irritated skin in healthy volunteers, Abstract and Poster presented at 14th World Congress on Pain (IASP), Buenos Aires, Argentina, October 6th -11th 2014



49. K. Schaffler, T. Brand, A. Borta, L. Nicolas, P. Reitmeir, J. Scholpp. Predictive Value of Laser Evoked Potentials & VAS - Exploring Anti-Nociceptive/Anti-Hyperalgesic Activity: Effects of Different Compound Classes on Normal, UVB and Capsaicin Irritated Skin in Healthy Human Volunteers, Abstract & Poster presented at 15th World Congress on Pain (IASP) Yokohama, Japan, September 26th -30th 2016
50. K. Schaffler, L. B. Nicolas, A. Borta, T. Brand, P. Reitmeir, R. Roebing, J. Scholpp. Investigation of the predictive validity of laser-EPs in normal, UVB-inflamed and capsaicin-irritated skin with four analgesic compounds in healthy volunteers, *Br J Clin Pharmacol.* 2017;83(7):1424-1435. doi: 10.1111/bcp.13247. Epub 2017 Feb 27 PMID: 28139023
51. K. Schaffler, A. Yassen, P. Reeh, P. Passier. A randomized, double-blind, placebo- and active comparator-controlled phase 1 study of analgesic/anti-hyperalgesic properties of ASP8477, a fatty acid amide hydrolase inhibitor, in healthy female subjects, *Pain Medicine* 2018;19,(6):1206-1218, <https://doi.org/10.1093/pm/pnx281> (2017)
52. K. Schaffler, A. Fakhoury, W. He, P. Passier, K. Tracy, J. Paul. A Phase 1, randomized, double-blind, laser evoked potential study to evaluate the analgesic/anti-hyperalgesic effect of ASP9226, a state-dependent N-type voltage-gated calcium channel inhibitor, in healthy male subjects, *Pain Medicine*, 2018;19,(11):2246-2255, <https://doi.org/10.1093/pm/pnx338>
53. K. Schaffler, Predictive validity of human Laser-EPs in extended phase-I IND analgesic research, Session VI: Emerging Tools and Approaches in Biomarker Discovery and Development, invited speech, abstract, NIH Pain Workshop: Discovery and Validation of Biomarkers to Develop Non-Addictive Therapeutics for Pain, Washington DC, Nov. 14-15, 2018
54. K. Schaffler, Laser-Evoked Potential (LEP) Model in Healthy Volunteers: its Validity to Predict Therapeutic Efficacy in Neuropathic Pain and Utility in Early Development Decision Making, ACCP Annual Meeting, invited speech, abstract, Symposium 13: Challenges of Neuroscience Drug Development & Role of Human Pharmacology Models in Early Development, ACCP, Chicago, Sept. 15-18, 2019

Contd. Below (compound list investigated with Laser-EPs at HPR)





List of compound examples (partially non-published) - done with Laser algesimetry:

Used Models:

Laser (Somatosensory) Evoked Potentials (LEPs) were done in normal as well as in capsaicin-irritated and UV_B-irradiated (hyperalgesic) skin.

1. Acetaminophen / Paracetamol oral
2. Alcohol i.v. and oral
3. 5-HT₃-Antagonist oral
4. ASA systemical and topical
5. B1-antagonist (oral + topical)
6. Benzoxazine oral
7. Ca-channel blockers/modulators (N- and T-type)
8. Codeine oral
9. CB1/2 partial agonist oral
10. CB1 agonist i.v.
11. Clonixin lysinate oral
12. CM40907/ Lodaxaprine AE oral (pyridazine derivative)
13. Dexketoprofen trometamol oral
14. Diclofenac i.v.
15. diverse selective COX2-Inhibitors (oral + i.v.): Celecoxib, Rofecoxib, Parecoxib, Valdecoxib, Etoricoxib
16. diverse galenic (racemic) Ibuprofen preparations and S-(+)-enantiomer oral
17. diverse local anaesthetic drugs/LAs (lozenges, gels and lotions): Lidocaine, Dimethindene
18. diverse **H1-antagonists** (oral + i.v. + topical): diphenhydramine, dimethindene, orphenadrine, exp. ReN1869
19. Dipyron / Metamizole i.v.
20. DMSO topical
21. Duloxetine oral
22. EP4 antagonist oral
23. Ethanol see above (alcohol)
24. Ethenzamide oral
25. Ethoxy-Benzoic Acid (EBA) solution oral
26. Etifoxine oral
27. Eugenol solution oral
28. FAAH inhibitor oral
29. Flupirtine oral
30. Gabapentin oral
31. Granisetron (oral)
32. Ibuprofen oral
33. Kappa-Agonist exp. (oral + i.v.)
34. Karprofen oral
35. Ketorolac oral
36. Lacosamide oral
37. Lidocaine (topical: at skin and oral cavity)
38. Lithium oral
39. Meprobamate oral
40. Metamizole/ Dipyron i.v.
41. Morphine IR oral
42. Naproxen oral
43. Nefopam oral
44. N-type CCA Z160 oral
45. N-type CCA ASP9226 oral
46. Neurin compound oral
47. NK1-antagonist (topical)
48. Orphenadrine i.v.
49. Oxycodon IR oral
50. Paracetamol / Acetaminophen oral
51. Pentazocine oral+i.v.
52. Pregabalin oral
53. Proteolytic enzymes oral
54. Propofol i.v.
55. Reboxetine oral
56. Remifentanil i.v.
57. Tapentadol oral
58. Tramadol, oral and i.v.
59. T-type CCA (Z944) oral
60. TRPV1 antagonist oral